Abstract
Background: Alzheimer's disease (AD) is a debilitating neurological illness of increasing prevalence. Because many patients are affected and current treatments have limited effectiveness, other therapeutic strategies are urgently needed. Objectives: Here we provide a review of the neurosurgical approaches that have been attempted or are currently being investigated for the treatment of AD. Methods: Computerized database searches identified all of the published studies in the English-language literature examining the surgical treatment of AD since 1950. Results: The following 5 categories of neurosurgical treatment were identified: cerebrospinal fluid shunting, intraventricular infusions, tissue grafting, gene therapy, and electrical neural stimulation. Conclusions: While none of the neurosurgical approaches applied to the treatment of AD have proven effective to date, recent trials involving gene therapy and electrical neural stimulation are showing promising early results. Larger trials investigating these treatments have been proposed or are currently under way.
Journal Section:
Editor's choice
References
1.
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression. Neuron 2005;45:651-660.
[PubMed]
2.
Lozano AM, Giacobbe P, Hamani C, Rizvi SJ, Kennedy SH, Kolivakis TT, Debonnel G, Sadikot AF, Lam RW, Howard AK, Ilcewicz-Klimek M, Honey CR, Mayberg HS: A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg 2012;116:315-322.
[PubMed]
3.
Denys D, Mantione M, Figee M, van den Munckhof P, Koerselman F, Westenberg H, Bosch A, Schuurman R: Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2010;67:1061-1068.
[PubMed]
4.
Appenzeller O, Salmon JH: Treatment of parenchymatous degeneration of the brain by ventriculo-atrial shunting of the cerebrospinal fluid. J Neurosurg 1967;26:478-482.
[PubMed]
5.
Salmon JH: Senile and presenile dementia: ventriculoatrial shunt for symptomatic treatment. Geriatrics 1969;24:67-72.
[PubMed]
6.
Silverberg GD, Levinthal E, Sullivan EV, Bloch DA, Chang SD, Leverenz J, Flitman S, Winn R, Marciano F, Saul T, Huhn S, Mayo M, McGuire D: Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology 2002;59:1139-1145.
[PubMed]
7.
Silverberg GD, Mayo M, Saul T, Fellmann J, Carvalho J, McGuire D: Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study. Neurology 2008;71:202-209.
[PubMed]
8.
Augustinsson LE, Blennow K, Blomstrand C, Brane G, Ekman R, Fredman P, Karlsson I, Kihlgren M, Lehmann W, Lekman A, Mansson JE, Ramstrom I, Wallin A, Wikkelso C, Gottfries CG, Svennerholm L: Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Dement Geriatr Cogn Disord 1997;8:26-33.
[PubMed]
9.
Eriksdotter-Jönhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Seiger, Shigeta M, Theodorsson E, Viitanen M, Winblad B, Wahlund LO: Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:246-257.
[PubMed]
10.
Harbaugh RE: Intracerebroventricular bethanechol chloride administration in Alzheimer's disease. Ann NY Acad Sci 1988;531:174-179.
[PubMed]
11.
Harbaugh RE, Reeder TM, Senter HJ, Knopman DS, Baskin DS, Pirozzolo F, Chui HC, Shetter AG, Bakay RA, Leblanc R, et al: Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease. Results of a collaborative double-blind study. J Neurosurg 1989;71:481-486.
[PubMed]
12.
Harbaugh RE, Roberts DW, Coombs DW, Saunders RL, Reeder TM: Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer's disease. Neurosurgery 1984;15:514-518.
[PubMed]
13.
Penn RD, Martin EM, Wilson RS, Fox JH, Savoy SM: Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials. Neurology 1988;38:219-222.
[PubMed]
14.
Read SL, Frazee J, Shapira J, Smith C, Cummings JL, Tomiyasu U: Intracerebroventricular bethanechol for Alzheimer's disease. Variable dose-related responses. Arch Neurol 1990;47:1025-1030.
[PubMed]
15.
Seiger A, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A, et al: Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res 1993;57:255-261.
[PubMed]
16.
Svennerholm L, Brane G, Karlsson I, Lekman A, Ramstrom I, Wikkelso C: Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement Geriatr Cogn Disord 2002;14:128-136.
[PubMed]
17.
Goldsmith HS: Treatment of Alzheimer's disease by transposition of the omentum. Ann NY Acad Sci 2002;977:454-467.
[PubMed]
18.
Rafael H, Mego R, Moromizato P, Espinoza M: Omental transplantation for Alzheimer's disease. Neurol India 2000;48:319-321.
[PubMed]
19.
Shankle WR, Hara J, Bjornsen L, Gade GF, Leport PC, Ali MB, Kim J, Raimo M, Reyes L, Amen D, Rudy L, O'Heany T: Omentum transposition surgery for patients with Alzheimer's disease: a case series. Neurol Res 2008;30:313-325.
[PubMed]
20.
Eriksdotter-Jönhagen M, Linderoth B, Lind G, Aladellie L, Almkvist O, Andreasen N, Blennow K, Bogdanovic N, Jelic V, Kadir A, Nordberg A, Sundstrom E, Wahlund LO, Wall A, Wiberg M, Winblad B, Seiger A, Almqvist P, Wahlberg L: Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:18-28.
[PubMed]
21.
Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J: A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11:551-555.
[PubMed]
22.
Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, Keren R, Wherrett J, Naglie G, Hamani C, Smith GS, Lozano AM: A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol 2010;68:521-534.
[PubMed]
23.
Turnbull IM, McGeer PL, Beattie L, Calne D, Pate B: Stimulation of the basal nucleus of Meynert in senile dementia of Alzheimer's type. A preliminary report. Appl Neurophysiol 1985;48:216-221.
[PubMed]
24.
Merrill CA, Jonsson MA, Minthon L, Ejnell H, H CsS, Blennow K, Karlsson M, Nordlund A, Rolstad S, Warkentin S, Ben-Menachem E, Sjogren MJ: Vagus nerve stimulation in patients with Alzheimer's disease: additional follow-up results of a pilot study through 1 year. J Clin Psychiatry 2006;67:1171-1178.
[PubMed]
25.
Sjogren MJ, Hellstrom PT, Jonsson MA, Runnerstam M, Silander HC, Ben-Menachem E: Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. J Clin Psychiatry 2002;63:972-980.
[PubMed]
26.
Fontaine D, Dueudon A, Lemaire JJ, Razzouk M, Viau P, Darcourt J, Robert P: Symptomatic treatment of memory decline in Alzheimer's disease by deep brain stimulation: a feasibility study. J Alzheimers Dis 2013;34:315-323.
[PubMed]
27.
Adams RD, Fisher CM, Hakim S, Ojemann RG, Sweet WH: Symptomatic occult hydrocephalus with ‘normal' cerebrospinal-fluid pressure. A treatable syndrome. N Engl J Med 1965;273:117-126.
[PubMed]
28.
Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H: Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-1562.
[PubMed]
29.
Bartus RT, Dean RL 3rd, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414.
[PubMed]
30.
Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH: Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987;329:65-68.
[PubMed]
31.
Hefti F: Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 1986;6:2155-2162.
[PubMed]
32.
Cannella MS, Oderfeld-Nowak B, Gradkowska M, Skup M, Garofalo L, Cuello AC, Ledeen RW: Derivatives of ganglioside GM1 as neuronotrophic agents: comparison of in vivo and in vitro effects. Brain Res 1990;513:286-294.
[PubMed]
33.
Leon A, Dal Toso R, Presti D, Benvegnu D, Facci L, Kirschner G, Tettamanti G, Toffano G: Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures. II. Modulatory effects of gangliosides. J Neurosci 1988;8:746-753.
[PubMed]
34.
Skaper SD, Katoh-Semba R, Varon S: GM1 ganglioside accelerates neurite outgrowth from primary peripheral and central neurons under selected culture conditions. Brain Res 1985;355:19-26.
[PubMed]
35.
Svennerholm L, Gottfries CG, Blennow K, Fredman P, Karlsson I, Mansson JE, Toffano G, Wallin A: Parenteral administration of GM1 ganglioside to presenile Alzheimer patients. Acta Neurol Scand 1990;81:48-53.
[PubMed]
36.
Goldsmith HS, Duckett S, Chen WF: Prevention of cerebral infarction in the dog by intact omentum. Am J Surg 1975;130:317-320.
[PubMed]
37.
Goldsmith HS, Duckett S, Chen WF: Prevention of cerebral infarction in the monkey by omental transposition to the brain. Stroke 1978;9:224-229.
[PubMed]
38.
Goldsmith HS, Chen WF, Duckett SW: Brain vascularization by intact omentum. Arch Surg 1973;106:695-698.
[PubMed]
39.
Goldsmith HS, Saunders RL, Reeves AG, Allen CD, Milne J: Omental transposition to brain of stroke patients. Stroke 1979;10:471-472.
[PubMed]
40.
Goldsmith HS: Omental transposition for Alzheimer's disease. Neurol Res 1996;18:103-108.
[PubMed]
41.
Goldsmith HS, Wu W, Zhong J, Edgar M: Omental transposition to the brain as a surgical method for treating Alzheimer's disease. Neurol Res 2003;25:625-634.
[PubMed]
42.
Goldsmith HS: A new approach to the treatment of Alzheimer's disease: the need for a controlled study. J Alzheimers Dis 2011;25:209-212.
[PubMed]
43.
Oliveira AA Jr, Hodges HM: Alzheimer's disease and neural transplantation as prospective cell therapy. Curr Alzheimer Res 2005;2:79-95.
[PubMed]
44.
Debinski W, Tatter SB: Convection-enhanced delivery to achieve widespread distribution of viral vectors: predicting clinical implementation. Curr Opin Mol Ther 2010;12:647-653.
[PubMed]
45.
Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008;70:1980-1983.
[PubMed]
46.
LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A: AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011;10:309-319.
[PubMed]
47.
Tuszynski MH, U HS, Amaral DG, Gage FH: Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 1990;10:3604-3614.
[PubMed]
48.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
[PubMed]
49.
Rosen WG: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
[PubMed]
50.
Bishop KM, Hofer EK, Mehta A, Ramirez A, Sun L, Tuszynski M, Bartus RT: Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol 2008;211:574-584.
[PubMed]
51.
Arvanitakis Z, Tuszynski M, Potkin S, Bartus R, Bennett D: A phase 1 clinical trial of CERE-110 (AAV-NGF) gene delivery in Alzheimer's disease. Am Acad Neurol Ann Meet, Boston, 2007.
52.
Wahlberg LU, Lind G, Almqvist PM, Kusk P, Tornoe J, Juliusson B, Soderman M, Sellden E, Seiger A, Eriksdotter-Jönhagen M, Linderoth B: Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J Neurosurg 2012;117:340-347.
[PubMed]
53.
Groves DA, Brown VJ: Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neurosci Biobehav Rev 2005;29:493-500.
[PubMed]
54.
Obeso JA, Guridi J, Rodriguez-Oroz MC, et al: Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-963.
[PubMed]
55.
Deuschl G, Schade-Brittinger C, Krack P, et al: A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
[PubMed]
56.
Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ: Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-2091.
[PubMed]
57.
Kupsch A, Benecke R, Müller J, Trottenberg T, Schneider G-H, Poewe W, Eisner W, Wolters A, Müller J-U, Deuschl G, Pinsker MO, Skogseid IM, Roeste GK, Vollmer-Haase J, Brentrup A, Krause M, Tronnier V, Schnitzler A, Voges J, Nikkhah G, Vesper J, Naumann M, Volkmann J: Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355:1978-1990.
[PubMed]
58.
Schuurman PR, Bosch DA, Bossuyt PMM, Bonsel GJ, van Someren EJW, de Bie RMA, Merkus MP, Speelman JD: A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000;342:461-468.
[PubMed]
59.
Vidailhet M, Vercueil L, Houeto J-L, Krystkowiak P, Benabid A-L, Cornu P, Lagrange C, Tézenas du Montcel S, Dormont D, Grand S, Blond S, Detante O, Pillon B, Ardouin C, Agid Y, Destée A, Pollak P: Bilateral deep brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005;352:459-467.
[PubMed]
60.
Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, Huang GD: Bilateral deep brain stimulation versus best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
[PubMed]
61.
Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S, Wheatley K: Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581-591.
[PubMed]
62.
Carlson JD, Cleary DR, Cetas JS, Heinricher MM, Burchiel KJ: Deep brain stimulation does not silence neurons in subthalamic nucleus in Parkinson's patients. J Neurophysiol 2010;103:962-967.
[PubMed]
63.
Clark KB, Smith DC, Hassert DL, Browning RA, Naritoku DK, Jensen RA: Posttraining electrical stimulation of vagal afferents with concomitant vagal efferent inactivation enhances memory storage processes in the rat. Neurobiol Learn Mem 1998;70:364-373.
[PubMed]
64.
Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, Lozano AM, Hammerstad J, Lyons K, Koller WC, Moeller JR, Eidelberg D: Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain 2001;124:1601-1609.
[PubMed]
65.
Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M, Lehrke R, Koulousakis A, Herholz K, Sturm V, Heiss WD: Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: Evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab 2004;24:7-16.
[PubMed]
66.
Karimi M, Golchin N, Tabbal SD, Hershey T, Videen TO, Wu J, Usche JWM, Revilla FJ, Hartlein JM, Wernle AR, Mink JW, Perlmutter JS: Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease. Brain 2008;131:2710-2719.
[PubMed]
67.
Nagaoka T, Katayama Y, Kano T, Kobayashi K, Oshima H, Fukaya C, Yamamoto T: Changes in glucose metabolism in cerebral cortex and cerebellum correlate with tremor and rigidity control by subthalamic nucleus stimulation in Parkinson's disease: a positron emission tomography study. Neuromodulation 2007;10:206-215.
[PubMed]
68.
Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD: Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62:42-52.
[PubMed]
69.
Greicius MD, Srivastava G, Reiss AL, Menon V: Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004;101:4637-4642.
[PubMed]
70.
Chase TN: Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann Neurol 1984;15(suppl):S170-S174.
[PubMed]
71.
Silverman DHS, Small GW, Chang CY, Lu CS, de Aburto MAK, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME: Positron emission tomography in evaluation of dementia. J Am Med Assoc 2001;286:2120-2127.
[PubMed]
72.
Laxton AW, Lozano AM: DBS for the treatment of Alzheimer's disease and dementias. World Neurosurg 2013;80:S28, e1-e8.
[PubMed]
73.
Clark KB, Krahl SE, Smith DC, Jensen RA: Post-training unilateral vagal stimulation enhances retention performance in the rat. Neurobiol Learn Mem 1995;63:213-216.
[PubMed]
74.
Sackeim HA, Keilp JG, Rush AJ, George MS, Marangell LB, Dormer JS, Burt T, Lisanby SH, Husain M, Cullum CM, Oliver N, Zboyan H: The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:53-62.
[PubMed]
75.
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression Of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S22-S32.
[PubMed]
76.
Freund H-J, Kuhn J, Lenartz D, Mai JK, Schnell T, Klosterkoetter J, Sturm V: Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation. Arch Neurol 2009;66:781-785.
[PubMed]
77.
Barnikol TT, Pawelczyk NBA, Barnikol UB, Kuhn J, Lenartz D, Sturm V, Tass PA, Freund H-J: Changes in apraxia after deep brain stimulation of the nucleus basalis of Meynert in a patient with Parkinson dementia syndrome. Mov Disord 2010;25:1519-1520.
[PubMed]
78.
Tsivilis D, Vann SD, Denby C, Roberts N, Mayes AR, Montaldi D, Aggleton JP: A disproportionate role for the fornix and mammillary bodies in recall versus recognition memory. Nat Neurosci 2008;11:834-842.
[PubMed]
79.
Browning PG, Gaffan D, Croxson PL, Baxter MG: Severe scene learning impairment, but intact recognition memory, after cholinergic depletion of inferotemporal cortex followed by fornix transection. Cereb Cortex 2010;20:282-293.
[PubMed]
80.
Wilson CR, Baxter MG, Easton A, Gaffan D: Addition of fornix transection to frontal-temporal disconnection increases the impairment in object-in-place memory in macaque monkeys. Eur J Neurosci 2008;27:1814-1822.
[PubMed]
81.
Mielke MM, Okonkwo OC, Oishi K, Mori S, Tighe S, Miller MI, Ceritoglu C, Brown T, Albert M, Lyketsos CG: Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease. Alzheimers Dement 2012;8:105-113.
[PubMed]
82.
Hescham S, Lim LW, Jahanshahi A, Steinbusch HW, Prickaerts J, Blokland A, Temel Y: Deep brain stimulation of the forniceal area enhances memory functions in experimental dementia: the role of stimulation parameters. Brain Stim 2013;6:72-77.
[PubMed]
83.
Hamani C, McAndrews MP, Cohn M, Oh M, Zumsteg D, Shapiro CM, Wennberg RA, Lozano AM: Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol 2008;63:119-123.
[PubMed]
84.
Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T: Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 2010;6:39-53.
[PubMed]
85.
Smith GS, Laxton AW, Tang-Wai DF, McAndrews MP, Diaconescu AO, Workman C, Lozano AM: Increased cerebral metabolism after one year of deep brain stimulation in Alzheimer's disease. Arch Neurol 2012;69:1141-1148.
[PubMed]
86.
Laxton AW, Dostrovsky JO, Lozano AM: Stimulation physiology in functional neurosurgery; in Lozano AM, Gildenberg PL, Tasker RR (eds): Textbook of Stereotactic and Functional Neurosurgery. Berlin, Springer, 2009, pp 1383-1399.
87.
Hamani C, Dubiela FP, Soares JCK, Shin D, Bittencourt S, Covolan L, Carlen PL, Laxton AW, Hodaie M, Stone SSD, Ha Y, Hutchison WD, Lozano AM, Mello LE, Oliveira MGM: Anterior thalamus deep brain stimulation at high current impairs memory in rats. Exp Neurol 2010;225:154-162.
[PubMed]
88.
Hamani C, Stone SS, Garten A, Lozano AM, Winocur G: Memory rescue and enhanced neurogenesis following electrical stimulation of the anterior thalamus in rats treated with corticosterone. Exp Neurol 2011;232:100-104.
[PubMed]
89.
Stone SSD, Teixeira CM, DeVito LM, Zaslavsky K, Josselyn SA, Lozano AM, Frankland PW: Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J Neurosci 2011;31:13469-13484.
[PubMed]
90.
Berger TW, Hampson RE, Song D, Goonawardena A, Marmarelis VZ, Deadwyler SA: A cortical neural prosthesis for restoring and enhancing memory. J Neural Eng 2011;8:046017.
[PubMed]
91.
Hampson RE, Gerhardt GA, Marmarelis V, Song D, Opris I, Santos L, Berger TW, Deadwyler SA: Facilitation and restoration of cognitive function in primate prefrontal cortex by a neuroprosthesis that utilizes minicolumn-specific neural firing. J Neural Eng 2012;9:056012.
[PubMed]
92.
Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM: The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosurg 2008;108:132-138.
[PubMed]
93.
Encinas JM, Hamani C, Lozano AM, Enikolopov G: Neurogenic hippocampal targets of deep brain stimulation. J Comp Neurol 2011;519:6-20.
[PubMed]
94.
Derrick BE, York AD, Martinez JL Jr: Increased granule cell neurogenesis in the adult dentate gyrus following mossy fiber stimulation sufficient to induce long-term potentiation. Brain Res 2000;857:300-307.
[PubMed]
95.
Bruel-Jungerman E, Davis S, Rampon C, Laroche S: Long-term potentiation enhances neurogenesis in the adult dentate gyrus. J Neurosci 2006;26:5888-5893.
[PubMed]
96.
Kitamura T, Saitoh Y, Murayama A, Sugiyama H, Inokuchi K: LTP induction within a narrow critical period of immature stages enhances the survival of newly generated neurons in the adult rat dentate gyrus. Mol Brain 2010;3:1-8.
[PubMed]
97.
Chun SK, Sun W, Park JJ, Jung MW: Enhanced proliferation of progenitor cells following long-term potentiation induction in the rat dentate gyrus. Neurobiol Learn Mem 2006;86:322-329.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
